Introduction
Sleep disorders are reported in Parkinson's disease, dementia with Lewy bodies, and Alzheimer' Disease [1, 2] . Although the pathophysiology of sleep disorders in these diseases remains unclear, it has been linked with reduced hypocretin levels in other sleep disorders such as narcolepsy [3, 4] . Hypocretins 1 and 2 (orexins A and B) are hypothalamic neuropeptides, initially identified and investigated as regulators of food intake, but which have more recently been shown to stimulate wakefulness [5, 6] .
Although recent studies in patients diagnosed with Parkinson's disease have reported a 60% reduction in hypothalamic hypocretin neurons [7] and Lewy bodies in hypocretin neurons of patients with advanced Parkinson's disease [8] , neuropathological hypocretin levels in dementia with Lewy bodies, or Alzheimer's disease remain unexamined.
This study aimed to examine neocortical hypocretin levels in dementia with Lewy bodies or Alzheimer's disease patients and to correlate these with patient-reported sleep habits and clinical characteristics.
Methods

Case selection and neuropathological evaluation
Autopsy material, from a total of 43 cases (Table 1) , was obtained from patients who received neurological and psychometric testing at the Alzheimer's Disease Research Center, San Diego, in the year preceding death.
A sleep evaluation was obtained including sleep difficulty, frequency, and leg movements during sleep.
At autopsy, the brains were divided sagittally, and left temporal cortex samples were fixed in 4% paraformaldehyde and sectioned at 40 mm for immunohistochemical analysis. Frozen samples from the right hemisphere were used for immunoblot analysis. The temporal cortex was selected as earlier studies have shown pathology and accumulation of a-synuclein in this region in patients with dementia with Lewy bodies [9, 10] .
For neuropathological diagnosis, paraffin sections from neocortical, limbic, and subcortical regions were stained with hematoxylin and eosin or thioflavine S [11, 12] , and the Braak stage was assessed [13] . On the basis of published clinical and pathological findings [14] , the cases were subdivided into nondemented age-matched controls (n = 3), Alzheimer's disease cases (n = 19), and dementia with Lewy bodies cases (n = 21). All the Alzheimer's disease cases met the Consortium to Establish a Registry for Alzheimer's disease and National Institute of Aging criteria for diagnosis and displayed neuritic plaques and tangle formation in the neocortex and limbic system [15] . The diagnosis of dementia with Lewy bodies was based on clinical presentation of dementia and pathological findings of Lewy bodies in the locus coeruleus, substantia nigra, or nucleus basalis of Meynert, and in the cortical regions. Lewy bodies were detected using an a-synuclein antibody as recommended by the Consortium on dementia with Lewy bodies criteria [15] . In addition to Lewy bodies, the majority of these cases displayed sufficient plaques and tangles to be classified as Braak stages III-IV; they had abundant plaques in the neocortex and limbic system but fewer tangles compared with the Alzheimer's disease cases.
Immunohistochemistry
As described earlier [16] , vibratome sections were washed in Tris-buffered saline (pH 7.4) and incubated at 41C overnight with antihypocretin 1 (1 : 500, Millipore, California, USA). Sections were incubated in secondary antibody (1 : 75, Vector, California, USA), followed by Avidin-D-horseradish peroxidase (Vector) and reacted with 0.2 mg/ml diaminobenzidine in 50 mM Tris (pH 7.4) with 0.001% H 2 O 2 . Sections were imaged with a digital Olympus microscope and analysis of hypocretin immunoreactivity was carried out using Image-Pro Plus (Media Cybernetics, Maryland, USA). For each case, three sections (10 images per section) were analyzed to estimate the average number of immunolabeled cells per unit area (mm 2 ) and the intensity of the immunostaining above the background levels (corrected optical density).
In control experiments, designed to test the specificity of the hypocretin antibody, preincubating the antibody with 20-fold excess of purified hypocretin protein eliminated immunoreactivity in the sections from the hypothalamus of a control case (data not shown).
Immunoblot analysis
The brains were homogenized in lysis buffer (1% Triton X-100, 10% glycerol, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 140 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 20 mM b-glycerophosphate, and proteinase inhibitor cocktails) and separated into cytosolic and membrane fractions by centrifugation (100 000 rpm, 60 min). For immunoblot, 20 mg of protein was resolved by SDS-polyacrylamide gel electrophoresis on 4-12% Bis-Tris gels (Invitrogen, California, USA) and transferred onto Immobilon membranes (Millipore). Membranes were blocked with phosphate-buffered saline with 0.2% Tween 20 containing 3% skim milk, followed by incubation with polyclonal antibodies against a-synuclein (Millipore) or hypocretin (Millipore). Membranes were incubated with secondary antibodies (1 : 5000, American Qualex, California, USA), visualized with enhanced chemiluminescence (PerkinElmer, Massachusetts, USA) and analyzed with the VersaDoc Gel Imaging System (BioRad, California, USA). Beta-actin (Sigma, California, USA) was used as a loading control.
Statistical analysis
Unless otherwise noted, all data are presented as mean ± SD. Analysis of variance with post-hoc analyses were carried out on biochemical markers. Given the degree of variability in the group sizes, nonparametric correlations were performed between biochemical markers and sleep questions for patients with dementia with Lewy bodies and Alzheimer's disease. Simple linear regression was performed on biochemical markers and sleep characteristics. Bonferroni's multiple comparison tests were conducted to account for multiple comparisons.
Results
Immunoblot analysis of cytosolic and membrane fractions from the neocortical brain homogenates of the cases with dementia with Lewy bodies, Alzheimer's disease, and controls was conducted to examine hypocretin levels. The antihypocretin antibody recognized a major band at approximately 4 kDa representing mature hypocretin and an additional band at 8 kDa likely representing prohypocretin. Levels of mature hypocretin were significantly reduced in the cytosolic fraction of the dementia with Lewy bodies cases compared with the controls (Fig. 1a ). A similar reduction was observed in the membrane fraction. No differences in cytosolic or membrane hypocretin levels were detected between the controls and Alzheimer's disease cases.
Abnormally aggregated accumulation of oligomeric asynuclein, a natively soluble and unfolded protein, is a key characteristic of Lewy bodies. Immunoblot analysis of a-synuclein levels in dementia with Lewy bodies, Alzheimer's disease, and controls showed significantly higher levels in dementia with Lewy bodies compared with Alzheimer's disease patients and controls in both the cytosolic and membrane portions (Fig. 1b) .
Consistent with the immunoblot analysis, immunohistochemical analysis of neocortical hypocretin levels in dementia with Lewy bodies, Alzheimer's disease, and controls showed reduced levels of neuronal (Fig. 2c , arrowheads) and fiber (Fig. 2d ) hypocretin compared with the controls (Fig. 2a, b , and g). No differences in patterns of neuronal or fiber hypocretin immunoreactivity were detected between the control and Alzheimer's disease cases ( Fig. 2e, arrowheads; Fig. 2f, arrow; Fig. 2g ).
Correlational analysis of clinical measures reported by dementia with Lewy bodies patients and levels of hypocretin or a-synuclein showed a significant correlation between the cytosolic hypocretin levels and hypersomnolence and a-synuclein levels in the membrane fraction (Table 2) . Moreover, in these cases, the levels of a-synuclein in the membrane fraction correlated with the presence and amount of leg movement. In Alzheimer's disease cases, hypocretin levels in the membrane fraction correlated with the amount of leg movement and sleep difficulties ( Table 3) .
Discussion
This study sought to investigate the levels of hypocretin, a hypothalamic neuropeptide associated with wakefulness, in dementia with Lewy bodies and Alzheimer's disease patients and its relationship with sleep abnormalitiesin these disorders. We show reduced neocortical hypocretin immunoreactivity in dementia with Lewy bodies compared with Alzheimer's disease patients and controls. Hypocretin levels in patients with dementia with Lewy bodies correlated with hypersomnolence and asynuclein accumulation. These results suggest that altered hypocretin levels may play a role in sleep abnormalities reported in dementia with Lewy bodies patients, as has been proposed for Parkinson's disease [7, 17] .
Recent studies have examined cerebrospinal fluid levels of hypocretin in Parkinson's disease and dementia with Lewy bodies; however, results have been inconclusive, with some studies reporting reductions [8, 17, 18] and others finding no alterations [19, 20] in either Parkinson's disease or dementia with Lewy bodies. These inconsistencies may be related to the reported need for a 50% reduction in hypocretin neurons to identify cerebrospinal fluid alterations [17] .
Our results are consistent with studies showing reduced cerebrospinal fluid levels of hypocretin in Parkinson's disease cases [8, 17, 18] and similar findings in experimental animal models [21] . We show a reduction of neocortical hypocretin-immunoreactive fibers and neurons in dementia with Lewy bodies cases compared with Alzheimer's disease and control. As most hypocretin is produced in the lateral hypothalamus [5, 22] , these hypocretin-immunoreactive neurons in the neocortex may represent uptake from projecting fibers. In contrast, the presence of hypocretin in these neurons may indicate that it is being produced by them, this is consistent with a study reporting the presence of prepro-hypocretin mRNA in pyramidal neurons in the hippocampus under basal conditions and during epilepsy [23] , indicating that hypocretin may be produced in cell populations other than the lateral hypothalamus.
Mechanisms underlying neocortical hypocretin reduction in dementia with Lewy bodies are unclear; however, we report a correlation between hypocretin levels and asynuclein aggregation in these patients, which is consistent with earlier studies in Parkinson's disease that have shown that a-synuclein accumulates in the hypocretin-containing neurons in the hypothalamus [7] . Alpha-synuclein has been shown to accumulate in the axons and interfere with axonal transport [24] ; therefore, one possibility is that the accumulation of a-synuclein in the neocortex may interfere with hypocretin transport. Therefore, further investigation of the relationship between a-synuclein aggregation and hypocretin levels is required to clarify this. Results are presented as just Spearman's rank correlation coefficients or Spearman's rank correlation coefficient (significance indicator). *Significance at the 0.05 level (two-tailed). **Significance at the 0.01 level (two-tailed).
Conclusion
Neocortical hypocretin levels are reduced in patients with dementia with Lewy bodies and correlate with hypersomnolence in these cases, suggesting a role for hypocretin in the sleep disturbances observed in patients with dementia with Lewy bodies.
